Immunic Aktie

Kaufen

Verkaufen

0,8801 USD -0,0382 USD -4,16 %

24.04.2026

NAS

Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Marktkap.102,24 Mio. EUR

WKNA2PHD4

ISINUS4525EP1011

SymbolIMUX

Immunic Aktien News

Sortieren:Datum Meistgelesen

13.05.26EQS GroupEQS-News: Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

30.04.26EQS GroupEQS-News: Immunic to Participate in Investor and Medical Conferences in May

28.04.26BenzingaImmunic Appoints New Medical Officer To Lead Clinical And Regulatory Strategy

28.04.26EQS GroupEQS-News: Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer

23.04.26EQS GroupEQS-News: Immunic, Inc. Announces 1-for-10 Reverse Stock Split

09.04.26EQS GroupEQS-News: Immunic to Participate in Scientific and Medical Conferences in April

01.04.26EQS GroupEQS-News: Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement

31.03.26EQS GroupEQS-News: Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton

10.03.26EQS GroupEQS-News: Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium

03.03.26EQS GroupEQS-News: Immunic to Participate in Investor Conferences in March

01.03.26finanzen.netImmunic präsentierte Bilanzzahlen zum jüngsten Jahresviertel

26.02.26EQS GroupEQS-News: Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update

20.02.26BenzingaWhat Does the Market Think About Immunic Inc?

13.02.26BenzingaWhy Is Immunic Stock Soaring Friday?

13.02.26BenzingaImmunic Stock Jumps After Pricing $400 Million Private Placement

13.02.26EQS GroupEQS-News: Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company

04.02.26EQS GroupEQS-News: Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

07.01.26EQS GroupEQS-News: Immunic Highlights 2025 Accomplishments and Upcoming Milestones

07.01.26PR NewswireImmunic Highlights 2025 Accomplishments and Upcoming Milestones

26.11.25EQS GroupEQS-News: Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

26.11.25PR NewswireImmunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

15.11.25finanzen.netImmunic gewährte Anlegern Blick in die Bücher

13.11.25EQS GroupEQS-News: Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

13.11.25PR NewswireImmunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

29.10.25EQS GroupEQS-News: Immunic to Participate in Industry and Investor Conferences in November

29.10.25PR NewswireImmunic to Participate in Industry and Investor Conferences in November

01.10.25EQS GroupEQS-News: Immunic to Participate in Scientific and Investor Conferences in October

01.10.25PR NewswireImmunic to Participate in Scientific and Investor Conferences in October

25.09.25EQS GroupEQS-News: Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

25.09.25PR NewswireImmunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

09.09.25EQS GroupEQS-News: Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

09.09.25PR NewswireImmunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

04.09.25EQS GroupEQS-News: Immunic to Participate in Investor and Scientific Conferences in September

04.09.25PR NewswireImmunic to Participate in Investor and Scientific Conferences in September

08.08.25finanzen.netImmunic legte die Bilanz zum abgelaufenen Quartal vor

07.08.25MotleyFoolImmunic (IMUX) Q2 Loss Widens 25%

07.08.25EQS GroupEQS-News: Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

07.08.25PR NewswireImmunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

24.06.25EQS GroupEQS-News: Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

24.06.25PR NewswireImmunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Immunic News

Immunic News: auf dieser Seite finden Sie alle Immunic News und Nachrichten zur Immunic Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Immunic News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Immunic News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.